Characteristics Associated with Discontinuation of Long-acting Reversible Contraception Within the First 6 Months of Use

Overview

Journal Obstet Gynecol

Specialty Gynecology & Obstetrics

Date 2013 Nov 9

PMID 24201685

Citations 46

Authors

Danielle S Grunloh

Teya Casner

Gina M Secura

Jeffrey F Peipert

Tessa Madden

Affiliations

Soon will be listed here.

Abstract

Objective: To measure discontinuation within 6 months among users of the levonorgestrel intrauterine system, copper intrauterine device (IUD), and etonogestrel implant and identify baseline characteristics associated with early discontinuation.

Methods: This was an analysis of the Contraceptive CHOICE Project, a cohort study of 9,256 participants provided with no-cost contraception and followed with telephone interviews at 3 and 6 months. We used logistic regression to investigate characteristics associated with early discontinuation of the two IUDs and implant and described reasons for discontinuation.

Results: A total of 6,167 participants were eligible for this analysis. Follow-up data were available for 5,928 participants; 5,495 (93%) were using their method at 6 months and 433 (7%) had discontinued. Discontinuation rates were 7.3%, 8.0%, and 6.9% for the levonorgestrel intrauterine system, copper IUD, and implant, respectively. After adjusting for age, race, marital status, low socioeconomic status, and history of sexually transmitted infection, we found that unmarried women were slightly more likely to discontinue compared with married women (adjusted odds ratio [OR] 1.26, 95% confidence interval [CI] 1.01-1.59 and adjusted OR 1.62, 95% CI 1.11-2.37, respectively). No other baseline characteristics, including younger age (14-19 years), were associated with early discontinuation. The most common reason given for discontinuation was cramping among IUD users and irregular or frequent bleeding among implant users.

Conclusion: Rates of discontinuation of long-acting reversible contraception at 6 months is low and not increased in adolescents and young women. Intrauterine devices and the implant should be considered as first-line contraceptive options among all women to reduce unintended pregnancy.

Level Of Evidence: : II.

Citing Articles

Discontinuation of long-acting reversible contraceptive methods and associated factors among reproductive-age women in Shashemene town, Oromia, Ethiopia.

Letose F, Tusa A, Sahlu D, Miherite Y Front Glob Womens Health. 2024; 5:1269302.

PMID: 38774251 PMC: 11106469. DOI: 10.3389/fgwh.2024.1269302.

Factors Affecting the Level of Adherence to Hypertension Medications: A Cross-Sectional Study Using the Hill-Bone Questionnaire.

Farah R, Alawwa I, Khateeb D, Hwidi B, Albdour K, Bani Monia O Patient Prefer Adherence. 2024; 18:893-904.

PMID: 38660626 PMC: 11042474. DOI: 10.2147/PPA.S457026.

A 3-year Retrospective Review of Contraceptive Initiation, Continuation, Switching, and Pregnancy Among Adolescents and Young Adults.

Kottke M, Aiyedipe S, Goedken P, Lyles R, McCool-Myers M J Adolesc Health. 2023; 74(4):794-800.

PMID: 38099900 PMC: 10960688. DOI: 10.1016/j.jadohealth.2023.11.010.

Reproductive Planning and the Choice of Long-acting Reversible Contraceptive Primary to Health: A Cross-Sectional Study.

Brufatto J, Dias T, Dabreu N, Rehder P Rev Bras Ginecol Obstet. 2023; 45(8):e456-e464.

PMID: 37683657 PMC: 10491473. DOI: 10.1055/s-0043-1772188.

Changes in hair cortisol concentration in intrauterine device initiators: A prospective cohort study.

Doty N, Beckley E, Garg B, Maristany S, Erikson D, Jensen J Contraception. 2023; 128:110142.

PMID: 37633589 PMC: 10842525. DOI: 10.1016/j.contraception.2023.110142.

References

Wong R, Bell R, Thunuguntla K, McNamee K, Vollenhoven B . Implanon users are less likely to be satisfied with their contraception after 6 months than IUD users. Contraception. 2009; 80(5):452-6. DOI: 10.1016/j.contraception.2009.03.021. View

Garbers S, Haines-Stephan J, Lipton Y, Meserve A, Spieler L, Chiasson M . Continuation of copper-containing intrauterine devices at 6 months. Contraception. 2012; 87(1):101-6. DOI: 10.1016/j.contraception.2012.09.013. View

Finer L, Zolna M . Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception. 2011; 84(5):478-85. PMC: 3338192. DOI: 10.1016/j.contraception.2011.07.013. View

Rosenstock J, Peipert J, Madden T, Zhao Q, Secura G . Continuation of reversible contraception in teenagers and young women. Obstet Gynecol. 2012; 120(6):1298-305. PMC: 4037699. DOI: 10.1097/aog.0b013e31827499bd. View

Gipson J, Koenig M, Hindin M . The effects of unintended pregnancy on infant, child, and parental health: a review of the literature. Stud Fam Plann. 2008; 39(1):18-38. DOI: 10.1111/j.1728-4465.2008.00148.x. View

Behringer T, Reeves M, Rossiter B, Chen B, Schwarz E . Duration of use of a levonorgestrel IUS amongst nulliparous and adolescent women. Contraception. 2011; 84(5):e5-e10. PMC: 3200533. DOI: 10.1016/j.contraception.2011.05.010. View

Secura G, Allsworth J, Madden T, Mullersman J, Peipert J . The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. Am J Obstet Gynecol. 2010; 203(2):115.e1-7. PMC: 2910826. DOI: 10.1016/j.ajog.2010.04.017. View

Singh S, Sedgh G, Hussain R . Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plann. 2011; 41(4):241-50. DOI: 10.1111/j.1728-4465.2010.00250.x. View

. ACOG Committee Opinion no. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol. 2010; 114(6):1434-1438. DOI: 10.1097/AOG.0b013e3181c6f965. View

10.

ONeil-Callahan M, Peipert J, Zhao Q, Madden T, Secura G . Twenty-four-month continuation of reversible contraception. Obstet Gynecol. 2013; 122(5):1083-1091. PMC: 4012225. DOI: 10.1097/AOG.0b013e3182a91f45. View

11.

Abdel-Aleem H, DArcangues C, Vogelsong K, Gulmezoglu A . Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev. 2007; (2):CD003449. DOI: 10.1002/14651858.CD003449.pub2. View

12.

Madden T, Mullersman J, Omvig K, Secura G, Peipert J . Structured contraceptive counseling provided by the Contraceptive CHOICE Project. Contraception. 2012; 88(2):243-9. PMC: 3660507. DOI: 10.1016/j.contraception.2012.07.015. View

13.

Finer L, Jerman J, Kavanaugh M . Changes in use of long-acting contraceptive methods in the United States, 2007-2009. Fertil Steril. 2012; 98(4):893-7. PMC: 3462302. DOI: 10.1016/j.fertnstert.2012.06.027. View

14.

Moreau C, Cleland K, Trussell J . Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007; 76(4):267-72. DOI: 10.1016/j.contraception.2007.06.008. View

15.

Madden T, Proehl S, Allsworth J, Secura G, Peipert J . Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. Am J Obstet Gynecol. 2011; 206(2):129.e1-8. PMC: 3268863. DOI: 10.1016/j.ajog.2011.09.021. View

16.

Jensen J, Nelson A, Costales A . Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception. 2007; 77(1):22-9. DOI: 10.1016/j.contraception.2007.09.006. View

17.

Winner B, Peipert J, Zhao Q, Buckel C, Madden T, Allsworth J . Effectiveness of long-acting reversible contraception. N Engl J Med. 2012; 366(21):1998-2007. DOI: 10.1056/NEJMoa1110855. View

18.

. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2012; 120(4):983-8. DOI: 10.1097/AOG.0b013e3182723b7d. View

19.

Peipert J, Zhao Q, Allsworth J, Petrosky E, Madden T, Eisenberg D . Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011; 117(5):1105-1113. PMC: 3548669. DOI: 10.1097/AOG.0b013e31821188ad. View

20.

Kavanaugh M, Frohwirth L, Jerman J, Popkin R, Ethier K . Long-acting reversible contraception for adolescents and young adults: patient and provider perspectives. J Pediatr Adolesc Gynecol. 2013; 26(2):86-95. PMC: 3672067. DOI: 10.1016/j.jpag.2012.10.006. View